Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alverine citrate + simeticone
- Development stage
- Phase 4
- Lead developer
- Mayoly Spindler
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alverine citrate + simeticone is a fixed-dose oral combination of two agents used primarily for the symptomatic treatment of irritable bowel syndrome (IBS) and related gastrointestinal disorders. Alverine citrate is an antispasmodic that relaxes smooth muscle in the gut, reducing abdominal pain and cramps by inhibiting serotonin-induced rectal hypersensitivity, likely through antagonism at the 5-HT1A receptor subtype[1][4][8]. Simeticone is an anti-foaming agent that reduces surface tension of gas bubbles in the digestive tract, facilitating their coalescence and expulsion to relieve bloating and discomfort[3][5][8]. The combination has demonstrated superior efficacy over placebo in relieving abdominal pain/discomfort associated with IBS, with a favorable safety profile[4][8]. It is widely marketed under various brand names internationally. Developers: Mayoly Spindler
- Brand names
- MeteospasmylAvarinDolospasmyl
- Other names
- alverine citrate and simeticoneACS (alverine citrate/simeticone combination)
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on alverine citrate + simeticone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alverine citrate + simeticone.